An Evaluation of Tebipenem In Vitro Activity Against a Panel of Pseudomonas aeruginosa Isolates with Efflux, AmpC, and OprD Mutations Posted on September 29, 2021 at 1:34 pm.Written by Spero Therapeutics View Presentation Post navigation Empiric Antimicrobial Prescribing for Urinary Tract Infections in Patients Discharged from the Emergency DepartmentHigh Prevalence of Fluoroquinolone-Resistant Urinary Tract Infection Among US Emergency Department Patients Diagnosed with UTI, 2018-2020